Covered recipient · General Payments record
TIMOTHY LEE MCCAVIT
Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology
General Payments · PY2018–2024
$43,632.44
- Reported across 47 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $15,086.00 | 2 |
| Travel and Lodging | $1,325.49 | 4 |
| Food and Beverage | $822.31 | 12 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $11,062.58 | 7 |
| Genentech USA, Inc. | $6,116.34 | 8 |
| PFIZER INC. | $33.66 | 2 |
| VERTEX PHARMACEUTICALS INCORPORATED | $21.22 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Genentech USA, Inc. | $170.65 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133125678 | CMS |
| Genentech USA, Inc. | $25.63 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133125683 | CMS |
| Genentech USA, Inc. | $57.63 | 10/18/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1133125687 | CMS |
| Genentech USA, Inc. | $5,310.00 | 10/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1133125691 | CMS |
| Genentech USA, Inc. | $79.41 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133125695 | CMS |
| Genentech USA, Inc. | $325.78 | 10/18/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1133125699 | CMS |
| Genentech USA, Inc. | $52.93 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133125703 | CMS |
| Genentech USA, Inc. | $94.31 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133125708 | CMS |
| GENZYME CORPORATION | $619.14 | 06/07/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1139742810 | CMS |
| GENZYME CORPORATION | $322.94 | 06/07/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1139742812 | CMS |
| GENZYME CORPORATION | $142.50 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139742814 | CMS |
| GENZYME CORPORATION | $43.33 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139742952 | CMS |
| GENZYME CORPORATION | $93.34 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139742954 | CMS |
| GENZYME CORPORATION | $65.33 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139742956 | CMS |
| GENZYME CORPORATION | $9,776.00 | 06/07/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1139742958 | CMS |
| PFIZER INC. | $16.42 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131789455 | CMS |
| PFIZER INC. | $17.24 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131969195 | CMS |
| VERTEX PHARMACEUTICALS INCORPORATED | $21.22 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105910508 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2022, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2022 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.